MX2019009106A - Anticuerpos procoagulantes. - Google Patents
Anticuerpos procoagulantes.Info
- Publication number
- MX2019009106A MX2019009106A MX2019009106A MX2019009106A MX2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A
- Authority
- MX
- Mexico
- Prior art keywords
- factor
- antibodies
- fixa
- binding
- activated form
- Prior art date
Links
- 239000003805 procoagulant Substances 0.000 title abstract 2
- 108010048049 Factor IXa Proteins 0.000 abstract 3
- 108010014173 Factor X Proteins 0.000 abstract 3
- 108010076282 Factor IX Proteins 0.000 abstract 2
- 108010074860 Factor Xa Proteins 0.000 abstract 2
- 102000013831 Coagulation factor IX Human genes 0.000 abstract 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 229940105774 coagulation factor ix Drugs 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos procoagulantes mejorados que incluyen anticuerpos biespecíficos capaces de unirse al factor de coagulación IX (FIX) o su forma activada IXa (FIXa) y opcionalmente al factor X (FX) y su forma activada Xa (FXa) y que promueven la activación de FX por FIXa, anticuerpos que unen sus epítopos y métodos y composición para tratar sujetos que padecen de una coagulopatía tal como hemofilia A.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017072796 | 2017-02-01 | ||
| CN2017105556 | 2017-10-10 | ||
| CN2017115210 | 2017-12-08 | ||
| EP18154489 | 2018-01-31 | ||
| PCT/EP2018/052550 WO2018141863A1 (en) | 2017-02-01 | 2018-02-01 | Procoagulant antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009106A true MX2019009106A (es) | 2019-09-10 |
Family
ID=61521468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009106A MX2019009106A (es) | 2017-02-01 | 2018-02-01 | Anticuerpos procoagulantes. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210388114A1 (es) |
| EP (2) | EP3577140A1 (es) |
| JP (3) | JP7366747B2 (es) |
| KR (1) | KR20190112747A (es) |
| CN (1) | CN110248964A (es) |
| AU (1) | AU2018216008A1 (es) |
| BR (1) | BR112019015611A2 (es) |
| CA (1) | CA3051639A1 (es) |
| CL (1) | CL2019002136A1 (es) |
| CO (1) | CO2019008461A2 (es) |
| IL (1) | IL268140B2 (es) |
| MX (1) | MX2019009106A (es) |
| PE (1) | PE20191347A1 (es) |
| PH (1) | PH12019501708A1 (es) |
| WO (1) | WO2018141863A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US11193588B2 (en) | 2017-08-09 | 2021-12-07 | Mainspring Energy, Inc. | Reinforced sealing rings |
| CN112513096B (zh) | 2018-08-01 | 2023-08-25 | 诺和诺德股份有限公司 | 改进的促凝血抗体 |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| WO2020114615A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
| TW202039583A (zh) * | 2018-12-07 | 2020-11-01 | 瑞士商巴克斯歐塔有限公司 | 結合因子IXa及因子X的蛋白分子 |
| WO2020114614A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
| WO2020115283A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
| KR20210118085A (ko) | 2018-12-21 | 2021-09-29 | 키맵 리미티드 | 공통 경쇄를 갖는 ＦＩＸａｘＦＸ 이중특이적 항체 |
| US20220298246A1 (en) * | 2019-07-03 | 2022-09-22 | Crystal Bioscience Inc. | Anti-b7-h3 antibody and methods of use thereof |
| JP2023512089A (ja) | 2020-01-30 | 2023-03-23 | ノヴォ ノルディスク アー／エス | 二重特異性第ｖｉｉｉ因子模倣抗体 |
| US20230287142A1 (en) * | 2020-07-06 | 2023-09-14 | President And Fellows Of Harvard College | Histamine binding polypeptides and uses thereof |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| US9062115B2 (en) * | 2010-09-22 | 2015-06-23 | Novo Nordisk A/S | Therapeutic factor VIII antibodies |
| TWI452136B (zh) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| EP2665751A1 (en) * | 2011-01-19 | 2013-11-27 | Bayer Intellectual Property GmbH | Binding proteins to inhibitors of coagulation factors |
| US20150110792A1 (en) * | 2011-11-22 | 2015-04-23 | Biogen Idec Ma Inc. | ANTI-TIM-1 Antibodies And Uses Thereof |
| CN105705517A (zh) * | 2013-11-07 | 2016-06-22 | 诺和诺德股份有限公司 | 用于治疗凝血障碍的新方法和抗体 |
| BR112017016952A2 (pt) * | 2015-04-17 | 2018-04-03 | F. Hoffmann-La Roche Ag | terapia de combinação com fatores de coagulação e anticorpos multiespecíficos |
-
2018
- 2018-02-01 EP EP18707852.2A patent/EP3577140A1/en not_active Withdrawn
- 2018-02-01 AU AU2018216008A patent/AU2018216008A1/en active Pending
- 2018-02-01 IL IL268140A patent/IL268140B2/en unknown
- 2018-02-01 CA CA3051639A patent/CA3051639A1/en active Pending
- 2018-02-01 MX MX2019009106A patent/MX2019009106A/es unknown
- 2018-02-01 JP JP2019541422A patent/JP7366747B2/ja active Active
- 2018-02-01 WO PCT/EP2018/052550 patent/WO2018141863A1/en unknown
- 2018-02-01 KR KR1020197024922A patent/KR20190112747A/ko not_active IP Right Cessation
- 2018-02-01 BR BR112019015611-9A patent/BR112019015611A2/pt unknown
- 2018-02-01 US US16/481,108 patent/US20210388114A1/en active Pending
- 2018-02-01 PE PE2019001503A patent/PE20191347A1/es unknown
- 2018-02-01 EP EP20212735.3A patent/EP3848396A1/en active Pending
- 2018-02-01 CN CN201880009891.3A patent/CN110248964A/zh active Pending
-
2019
- 2019-07-25 PH PH12019501708A patent/PH12019501708A1/en unknown
- 2019-07-30 CL CL2019002136A patent/CL2019002136A1/es unknown
- 2019-08-01 CO CONC2019/0008461A patent/CO2019008461A2/es unknown
-
2021
- 2021-07-29 JP JP2021124447A patent/JP2021176898A/ja active Pending
-
2023
- 2023-10-05 JP JP2023173586A patent/JP2023179628A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018216008A1 (en) | 2019-08-01 |
| JP7366747B2 (ja) | 2023-10-23 |
| EP3577140A1 (en) | 2019-12-11 |
| PH12019501708A1 (en) | 2020-06-01 |
| JP2021176898A (ja) | 2021-11-11 |
| WO2018141863A9 (en) | 2018-11-22 |
| TW201835107A (zh) | 2018-10-01 |
| CO2019008461A2 (es) | 2020-01-17 |
| IL268140A (en) | 2019-09-26 |
| CN110248964A (zh) | 2019-09-17 |
| JP2020506927A (ja) | 2020-03-05 |
| PE20191347A1 (es) | 2019-09-30 |
| BR112019015611A2 (pt) | 2020-03-17 |
| RU2019125970A3 (es) | 2021-06-18 |
| IL268140B2 (en) | 2024-04-01 |
| CA3051639A1 (en) | 2018-08-09 |
| EP3848396A1 (en) | 2021-07-14 |
| JP2023179628A (ja) | 2023-12-19 |
| US20210388114A1 (en) | 2021-12-16 |
| IL268140B1 (en) | 2023-12-01 |
| WO2018141863A1 (en) | 2018-08-09 |
| CL2019002136A1 (es) | 2019-10-18 |
| RU2019125970A (ru) | 2021-03-02 |
| KR20190112747A (ko) | 2019-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501708A1 (en) | Procoagulant antibodies | |
| PH12021550117A1 (en) | Improved procoagulant antibodies | |
| PH12019501126A1 (en) | Bispecific antibodies binding to coagulation factor ix and ciagulation factor x | |
| PH12017502358A1 (en) | Factor xi antibodies and methods of use | |
| CY1124118T1 (el) | Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων | |
| EA201691470A1 (ru) | Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека | |
| SA518390944B1 (ar) | أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| EA201890834A1 (ru) | Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения | |
| TW200730624A (en) | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 | |
| TW200745162A (en) | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 | |
| JO3701B1 (ar) | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي | |
| EA201490850A1 (ru) | Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения | |
| EA201690064A1 (ru) | Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения | |
| PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
| EA201590918A1 (ru) | Антитела к bmp-6 | |
| MY184189A (en) | Methods of treating nail and scalp psoriasis | |
| MX2019013700A (es) | Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand. | |
| NZ629700A (en) | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| AR114539A1 (es) | Anticuerpos procoagulantes mejorados | |
| PH12016501608A1 (en) | Peptides and methods of use | |
| EA201991246A1 (ru) | Моно- и биспецифические антитела, связывающиеся с фактором коагуляции ix и фактором коагуляции x | |
| NZ626296A (en) | Compositions and methods for antibodies targeting factor p |